DelveInsights Estrogen Receptor Positive (ER+) Breast Cancer - Market Insights, Epidemiology and Market Forecast-2023- US Reports provides an overview of the disease and global market size of the Estrogen Receptor Positive (ER+) Breast Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Estrogen Receptor Positive (ER+) Breast Cancer from 2013-2023. According to DelveInsight, the forecasted patient population of ER+ breast cancer will increase at a CAGR of 2.03% from 2015 to 2023 and the worldwide ER+ breast cancer market is estimated to be 2.86 billion by 2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Note: This report will be delivered to the client in 48 hours
Report covers the disease overview, current treatment options, prescription drugs and emerging therapies.
The Report also covers the detailed global historical and forecasted epidemiological data covering United States from 2013-2023.
It also provides Market size of Estrogen Receptor Positive (ER+) Breast Cancer for United States and forecasted Market size to 2023.
Table of Contents
1 Report Introduction
2 Executive Summary
3 ER+ Breast Cancer Market Overview at a Glance
Worldwide Market Size of ER+ Breast Cancer in 2013
Worldwide Market Size of ER+ Breast Cancer in 2023
4 Treatment Landscape
Treatment Options by Stage
Stage IIB, Stage IIC, Stage IIIA, Stage, IIIB, Stage IIIC, Stage IV
5 Epidemiology and Patient Population
Population and Forecast Methodology
Total Incident Cases
Diagnosed Drug Treated Population
Percentage Drug Treated
6 Current Medical Practice and Therapies in Use
Overview of ER+ Breast Cancer
Currently Medical Practice
Overview of ER+ Breast Cancer Drug Classification
Prescription Drugs, Dosing & Route
7 Emerging Therapies
Late Stage Pipeline Overview
Expected Launch date of these therapies in United States
Late Stage Pipeline Analysis
Efficacy & Safety Results
8 United States Market Assessment
United States Market Forecast
United States Market Size
Market Driver and Constraints
Factors Driving the Market for ER+ Breast Cancer
Factors Constraining the Market for ER+ Breast Cancer
9 Consulting Services
11 About DelveInsight
Make an enquiry before buying this Report
Please fill the enquiry form below.